News 
Market Data 
Discover
Nadendla
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
time to fly!
The next leg of adventure and action should begin soon!!
Breaking NEWS PharmStar Pharmaceuticals CEO Howard Phykitt to Host Conference Call Today at 4:15 PM ET To join the call, please dial 712-432-3900 approximately 5 to 10 minutes before the start of the call and when prompted, enter conference code 594265#. Attendees are asked to submit any questions prior to the start of the call via email to cc@pharmstarinc.com. Listeners may tune into the live show by visiting http://www.billchippasshow.com. The Company has received an offer to purchase the building, and is currently assessing the offer. Mr. Phykitt concluded, "I made a commitment to shareholders when we restructured the capitalization table that the Company has no need to dilute its common stock for at least the next six months. This decision will not affect that commitment."
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=62926766
Pharmstar Pharm (USOTC:PHAR)
Intraday Stock Chart
Today : Tuesday 10 May 2011
PharmStar Pharmaceuticals, Inc., (PINKSHEETS: PHAR) (the "Company"), a U.S. drug developer, manufacturer and marketer of the FDA-approved, Over-the-Counter (OTC) liquid pain reliever Aquaprin™, today announced that Company CEO Howard Phykitt will hold an investor conference call today at 4:15 pm Eastern Time to discuss the current status of the Company's initiatives. All interested parties are invited to participate.
Additionally, Mr. Phykitt will be featured on the Bill Chippas Show this morning, Tuesday, May 10, 2011, at 10:15 am Eastern Time.
About PharmStar Pharmaceuticals
PharmStar Pharmaceuticals, Inc. is a U.S.-based drug development, manufacturing and marketing company and the innovator of Aquaprin™, an FDA-approved, OTC liquid pain reliever. In development since 1993 with over $3 million invested to-date, Aquaprin™ is a liquid derivative of aspirin based on a patent-pending formula. The product is designed to dissolve nearly instantly in just 1.5 ounces of water, which can be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset. For more information, visit www.pharmstarinc.com.
PHAR Property Appraisal Valued at $32 Million
Date : 05/09/2011 @ 1:21PM
Source : MarketWire
Stock : PharmStar Pharmaceuticals, Inc. (PHAR)
Quote : 0.032 0.002 (6.67%) @ 2:02PM
http://news.morningstar.com/all/market-wire/11753738/pharmstar-pharmaceuticals-receives-updated-intellectual-property-appraisal-valued-at-32-million.aspx
((wow~DD))= http://t.co/k1ffD7a , http://t.co/8eGBQGn 
PharmStar Pharmaceuticals Receives Updated Intellectual Property Appraisal Valued at $32 Million
Pharmstar Pharm (USOTC:PHAR)
Intraday Stock Chart
Today : Monday 9 May 2011
PharmStar Pharmaceuticals, Inc., (PINKSHEETS: PHAR) (the "Company"), a U.S. drug developer, manufacturer and marketer of the FDA-approved, Over-the-Counter (OTC) liquid pain reliever Aquaprin™, today announced that it has received an updated appraisal for the Company's intellectual property. The new report states that the intellectual property associated with the patent, know-how and trademark positions of PharmStar Pharmaceuticals is valued at $32 million
. The report was filed as a supplemental information disclosure with the OTC Markets on May 6, 2011 and may be found at www.otcmarkets.com/stock/PHAR/financials, under the "Supplemental Information -- PharmStar IP Valuation."
The appraisal report was provided by Hultquist IP, a firm that represents clients in intellectual property matters in a wide variety of technologies, including: chemical, biological, electronic, solid-state, mechanical, and information technologies. According to the Hultquist report, "This total present value of $32 million is determined to be the value of the intellectual property rights associated with the Aquaprin™ product and the Insta-prin™ applicator product, since in the absence of the intellectual property applicable to these products, commercialization would not be viable, and there would be no barrier to entry to far larger competitors with correspondingly larger resources. The exclusionary rights associated with the proprietary patent position of PSP, together with the branding trademarks, and substantial know-how of Howard Phykitt, warrant such valuation. We therefore conclude that the intellectual property rights relating to the Aquaprin™ product and the Insta-prin™ applicator product are fairly valued at $32 million."
On April 28, 2011, the Company filed its Quarterly Report for the first quarter of 2011. In the report, the Company recognized the value of its Intellectual Property and Patents, Research and Development of Patents at a total of $13,104,549. The Company will continue to list these assets at their imputed book value, rather than the determined market value pursuant to the report.
"Though we are pleased with the valuation ascribed to the Aquaprin™ product line by Hultquist IP, we believe that the prudent course of action at this time is to continue to show the value of our core assets at book value. We will do so until such a time as the Company is in full production, or has a clear and substantial reason to modify the said valuation," stated Howard Phykitt, Chairman and CEO of PharmStar.
About PharmStar Pharmaceuticals
PharmStar Pharmaceuticals, Inc. is a U.S.-based drug development, manufacturing and marketing company and the innovator of Aquaprin™, an FDA-approved Over-the-Counter (OTC) liquid pain reliever. In development since 1993 with over $3 million invested to-date, Aquaprin™ is a liquid derivative of aspirin based on a patent-pending formula. The product is designed to dissolve nearly instantly in just 1.5 ounces of water, which can be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset. PharmStar's headquarters are located in Rocky Mount, NC. For more information, visit www.pharmstarinc.com.
PHAR Financials out before yesterdays close showing
31M assets 50k liabilities
12m float as of 4-8
Clean balance sheet
FDA Approved "Aquaprin"
also..
Just upgraded to Pinksheets "Current Information" 4-14
Buying a NEW FDA Approved facility
CEO has put in writing NO DILUTION for at least 6 mos(HUGE)
Insiders shares restricted for min 1yr(awesome)
http://ih.advfn.com/p.php?pid=nmona&article=47333789
3.There is no need to increase Authorized Shares at this time, and the company does not anticipate having to increase its Authorized anytime in the near future.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=62802709
just look under Liabilities:
http://www.otcmarkets.com/otciq/ajax/showFinancialReportById.pdf?id=48798
Accounts payable-0-
Notes payable-0-
Notes payable to related parties-0-
Legal fees payable-0-
Licenses deposit Pharma Cap= 50,000
The ONLY Liability that Pharmstar has PERIOD is a $50,000 licensing fee for a Pharma bottle cap for the companies Instaprin product.
Why PHAR seen here
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=62514099
http://www.pharmstarinc.com/why_aquaprin.html
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=62082217
BIG BANG!!!!!
PHAR!!!! DEMON RUN IN PROGRESS!!
AI
